Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.36B P/E - EPS this Y - Ern Qtrly Grth -
Income -614.93M Forward P/E -1.81 EPS next Y -20.80% 50D Avg Chg -6.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 10.21 EPS next 5Y - 52W High Chg -66.00%
Recommedations 1.00 Quick Ratio 9.17 Shares Outstanding 701.70M 52W Low Chg 195.00%
Insider Own 88.15% ROA -12.79% Shares Float 82.93M Beta -1.20
Inst Own 4.89% ROE -601.85% Shares Shorted/Prior 21.81M/15.95M Price 1.95
Gross Margin - Profit Margin - Avg. Volume 1,987,951 Target Price 6.50
Oper. Margin - Earnings Date May 9 Volume 1,129,333 Change -6.70%
About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics Inc. News
04/11/24 Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
04/10/24 Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
04/02/24 Insiders Are Buying These 11 Penny Stocks
03/29/24 Why Summit Therapeutics Stock Crushed the Market This Week
03/25/24 Summit Therapeutics Insiders Up US$5.1m On US$5.05m Investment
03/22/24 Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
03/14/24 Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
03/05/24 Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
02/21/24 Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript
02/21/24 Q4 2023 Summit Therapeutics Inc Earnings Call
02/20/24 Summit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ...
02/20/24 Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
02/14/24 Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
02/07/24 Summit Therapeutics to Present at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
01/08/24 Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
01/03/24 Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
11/27/23 Insiders hold 82% of Summit Therapeutics Inc. (NASDAQ:SMMT), and they've been buying recently
11/08/23 Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript
11/07/23 Summit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational Progress
11/07/23 Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
SMMT Chatroom

User Image Dreamer777 Posted - 9 hours ago

$SMMT Ivonescimab has been approved for marketing in China by the National Medical Products Administration (NMPA), and its new drug application (NDA) has been submitted to the US Food and Drug Administration (FDA) ².

User Image Dreamer777 Posted - 13 hours ago

$SMMT Akeso Biopharma has announced positive interim data from its Phase III trial of cadonilimab and xelox as a first-line therapy for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJAC). Summit has the right partner.

User Image Tommy_Two_Toes Posted - 1 day ago

$SMMT be careful here. Lopsided af. Not a ton of time. I’m taking a small stab at it. Don’t be like me, prob. Unless you took one or more of the plays today that went 100%+.

User Image WallStJesus Posted - 1 day ago

$SMMT Put/Call: 19/1844

User Image Dreamer777 Posted - 2 days ago

$SMMT Miami, Florida, April 11, 2024 – Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit, ” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately

User Image Dreamer777 Posted - 3 days ago

$SMMT NEWSWIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncology Forum, which will be held virtually April 16-17, 2024. Dr. Maky Zanganeh, Chief Executive Officer and President, Robert W. Duggan, Chairman and Chief Executive Officer, Manmeet Soni, Chief Operating Officer & Chief Financial Officer, Dave Gancarz, Chief Business & Strategy Officer, and Dr. Allen S. Yang, Chief Medical Officer, will participate in a fireside chat on behalf of our organization surrounding the development of our innovative investigational bispecific antibody, ivonescimab, on Tuesday April 16, 2024 at 2:30pm ET.

User Image SenorDG Posted - 3 days ago

$SMMT bearish on $Pastor100

User Image SenorDG Posted - 3 days ago

$SMMT

User Image TruthBroker2 Posted - 3 days ago

$PLSE $SMMT

User Image TruthBroker2 Posted - 3 days ago

$SMMT

User Image Pastor100 Posted - 3 days ago

$SMMT Snake oil dip is thanks to the Israel Iran war.

User Image Mr_2B Posted - 6 days ago

$SMMT the newly added member is a significant asset. Those in biotechs know his values. I added more shares and will buy even more on Monday if there is more dip.

User Image Mr_2B Posted - 6 days ago

$MCRB outta this grabge into $SMMT.

User Image Max22 Posted - 6 days ago

$SMMT after some signs of rejection earlier in the week, strong selloff on friday which points to some degree of continuation next week.

User Image Dreamer777 Posted - 6 days ago

$SMMT Buy here April 16 is Stifel oncology conference and Maky is presenting

User Image Dreamer777 Posted - 6 days ago

$SMMT with 446k volume came down. who would sell on the eve of Akeso reporting third phase results?

User Image TruthBroker2 Posted - 6 days ago

$SMMT Another addition to the Dream Team Genomics specialist why not .Genius

User Image Dreamer777 Posted - 1 week ago

$SMMT This has nothing to do with inflation or interest rates. Actually it is refuge from other equities dependent on rates and inflation.

User Image TruthBroker2 Posted - 1 week ago

$SMMT Team Summit.

User Image Stock_Titan Posted - 1 week ago

$SMMT Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum https://www.stocktitan.net/news/SMMT/summit-therapeutics-to-present-at-the-stifel-2024-targeted-oncology-vwml7nvnd027.html

User Image Americanbulls Posted - 1 week ago

$SMMT apparently the bear pattern is not confirmed. Prices continue to rise. www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=SMMT

User Image TruthBroker2 Posted - 1 week ago

$SMMT

User Image TruthBroker2 Posted - 1 week ago

$SMMT $PLSE

User Image Dreamer777 Posted - 1 week ago

$SMMT Analysts are upbeat about the company’s earnings outlook from here. Citibank recently revised up its Akeso revenue forecast by 10% this year and 6% for 2025, expressing optimism about the commercial prospects for the bispecific drug ivonescimab, which is going through clinical trials. Results for the new PD-1/VEGF drug are due for release in the second quarter.

User Image TG770 Posted - 1 week ago

@RedBarnCannabis 💕 take a look at $SMMT

User Image kevinwoods Posted - 1 week ago

$SMMT 1 million shares bought in the last3 minutes. What’s that all about

User Image Cybraham Posted - 1 week ago

$SMMT

User Image kevinwoods Posted - 1 week ago

$SMMT let’s get some

User Image eroman Posted - 2 weeks ago

$SMMT want to double down so bad but if it drops 3.30s we're toast, if it stays here/ recovers a couple cents looks like a great entry point

User Image eroman Posted - 2 weeks ago

$SMMT I would prefer if you stopped bending me over

Analyst Ratings
Stifel Buy Mar 26, 24
HC Wainwright & Co. Neutral Nov 18, 20
HC Wainwright & Co. Buy Mar 19, 20
Janney Montgomery Scott Neutral Jun 28, 18
SunTrust Robinson Humphrey Hold Jun 27, 18
Janney Montgomery Scott Buy May 2, 18
BTIG Buy Feb 13, 18
Oppenheimer Outperform Jan 26, 18
SunTrust Robinson Humphrey Buy Jan 4, 18
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zanganeh Mahkam Chief Executive Offi.. Chief Executive Officer Dec 11 Buy 2.07 5,000 10,350 494,814 12/13/23
Zanganeh Mahkam Co-CEO & President Co-CEO & President Mar 08 Buy 1.05 23,527,044 24,703,396 9,884,095 03/13/23
Dhingra Ankur Chief Financial Offi.. Chief Financial Officer Aug 16 Buy 0.97 37,685 36,554 38,196 03/08/23
DUGGAN ROBERT W Chief Executive Offi.. Chief Executive Officer Aug 16 Buy 0.97 94,849,203 92,003,727 162,532,792 08/18/22
Zanganeh Maky Co-CEO & President Co-CEO & President Aug 16 Buy 0.97 5,809,132 5,634,858 3,135,466 08/18/22
Dhingra Ankur Chief Financial Offi.. Chief Financial Officer Aug 16 Buy 0.97 36,215 35,129 38,196 08/17/22